SPRO
Spero Therapeutics, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Spero Therapeutics (SPRO) Stock: Buy, Sell, or Hold?
$1.00
0.00 (-0.01%)
▼
5d:
-2.92%
30d:
-11.51%
90d:
-15.97%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (50%)
Quality Score
47/100
Position
OVERSOLD
30-Day Fair Range
$1.04 – $1.17
Position: OVERSOLD
Forward P/E & Valuation
-9.5x
CHEAP
vs 6.5x historical avg
Wall Street Target
$5.33
+433.4% upside
Options IV & Volume
82th pct IV
HIGH volume confirmation
Support / Resistance
$0.95 / $1.11
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: SPRO shows conflicting indicators. Wait for confirmation before entering.
Get Alerted When SPRO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: SPRO is currently trading at $1.00, which is considered oversold relative to its 30-day fair value range of $1.04 to $1.17. From a valuation perspective, the stock is trading at a discount (Forward PE: -9.5) compared to its historical average (6.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SPRO is in a strong downtrend. Immediate support is located at $0.95, while resistance sits at $1.11.
Market Sentiment: SPRO scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Implied Volatility is high (82th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $5.33 (+433.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SPRO is in a strong downtrend. Immediate support is located at $0.95, while resistance sits at $1.11.
Market Sentiment: SPRO scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Implied Volatility is high (82th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $5.33 (+433.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.04 -
$1.17
Company Quality Score
47/100
(HOLD)
Options IV Signal
82th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
50.0%
Trading Range & Key Levels
30-Day Trading Range
$1.04 -
$1.17
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.35
(35.1%)
Support Level
$0.95
Resistance Level
$1.11
Current Trend
Strong Downtrend
Technical data as of
Nov 13, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BEARISH: Options expensive (IV 82th percentile)
- BEARISH: Weak technical setup (39/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 433.4% below Wall St target ($5.33)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 47/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-9.52
Wall Street Target
$5.33
(+433.4%)
Revenue Growth (YoY)
-95.6%
Earnings Growth (YoY)
75.3%
Profit Margin
15.7%
PE vs Historical
-9.5 vs 6.5
CHEAP
Share SPRO Analysis
Share this live SPRO analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (SPRO)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 13, 2026
Daily AI digest
AI Retail Discussion Summary:
Spero Therapeutics reported third-quarter financial results and provided a business update, focusing on the advancement of SP001 toward a Phase 2 study in IgG4-related disease.
Key Retail Themes:
Advancement of SP001 in clinical trials
Partnership with GSK
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 13, 2026 6:03 PM ET
Data refreshes hourly during market hours. Next update: 7:03 PM
Data refreshes hourly during market hours. Next update: 7:03 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SPRO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$302 | 60 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$592 | 40 SELL |
|
ONC
BeOne Medicines AG |
STRONG BUY
27 analysts |
$438 | 36 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$304 | 39 SELL |
|
KURA
Kura Oncology Inc |
STRONG BUY
16 analysts |
$32 | 63 BUY |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive SPRO Research Pages